184 related articles for article (PubMed ID: 8548536)
1. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease.
Martins-Filho OA; Pereira ME; Carvalho JF; Cançado JR; Brener Z
Clin Diagn Lab Immunol; 1995 Sep; 2(5):569-73. PubMed ID: 8548536
[TBL] [Abstract][Full Text] [Related]
2. Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.
Martins-Filho OA; Eloi-Santos SM; Teixeira Carvalho A; Oliveira RC; Rassi A; Luquetti AO; Rassi GG; Brener Z
Clin Diagn Lab Immunol; 2002 Sep; 9(5):1107-13. PubMed ID: 12204967
[TBL] [Abstract][Full Text] [Related]
3. Anti-Trypanosoma cruzi and anti-laminin antibodies in chagasic patients after specific treatment.
Gazzinelli RT; Galvão LM; Cardoso JE; Cançado JR; Krettli AU; Brener Z; Gazzinelli G
J Clin Microbiol; 1988 Sep; 26(9):1795-800. PubMed ID: 3141467
[TBL] [Abstract][Full Text] [Related]
4. Innovations in diagnosis and post-therapeutic monitoring of Chagas disease: Simultaneous flow cytometric detection of IgG1 antibodies anti-live amastigote, anti-live trypomastigote, and anti-fixed epimastigote forms of Trypanosoma cruzi.
Alessio GD; Côrtes DF; Machado de Assis GF; Júnior PA; Ferro EA; Antonelli LR; Teixeira-Carvalho A; Martins-Filho OA; de Lana M
J Immunol Methods; 2014 Nov; 413():32-44. PubMed ID: 25064148
[TBL] [Abstract][Full Text] [Related]
5. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease.
Cordeiro FD; Martins-Filho OA; Da Costa Rocha MO; Adad SJ; Corrêa-Oliveira R; Romanha AJ
Clin Diagn Lab Immunol; 2001 Jan; 8(1):112-8. PubMed ID: 11139203
[TBL] [Abstract][Full Text] [Related]
6. Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory.
Vitelli-Avelar DM; Sathler-Avelar R; Wendling AP; Rocha RD; Teixeira-Carvalho A; Martins NE; Dias JC; Rassi A; Luquetti AO; Elói-Santos SM; Martins-Filho OA
J Immunol Methods; 2007 Jan; 318(1-2):102-12. PubMed ID: 17161421
[TBL] [Abstract][Full Text] [Related]
7. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease.
Gazzinelli RT; Galvao LM; Krautz G; Lima PC; Cancado JR; Scharfstein J; Krettli AU
Am J Trop Med Hyg; 1993 Nov; 49(5):625-35. PubMed ID: 8250103
[TBL] [Abstract][Full Text] [Related]
8. Effect of protective and non-protective antibodies in the phagocytosis rate of Trypanosoma cruzi blood forms by mouse peritoneal macrophages.
Lages-Silva E; Ramirez LE; Krettli AU; Brener Z
Parasite Immunol; 1987 Jan; 9(1):21-30. PubMed ID: 3104865
[TBL] [Abstract][Full Text] [Related]
9. Lytic antibodies in Trypanosoma cruzi-infected persons with low parasitemia.
Zulantay I; Venegas J; Apt W; Solari A; Sanchez G
Am J Trop Med Hyg; 1998 Jun; 58(6):775-9. PubMed ID: 9660462
[TBL] [Abstract][Full Text] [Related]
10. Epitopes common to Trypanosoma cruzi and mammalian tissues are recognized by sera from Chagas' disease patients: prognosis value in Chagas disease.
Laucella SA; de Titto EH; Segura EL
Acta Trop; 1996 Dec; 62(3):151-62. PubMed ID: 9025983
[TBL] [Abstract][Full Text] [Related]
11. Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.
Krautz GM; Galvão LM; Cançado JR; Guevara-Espinoza A; Ouaissi A; Krettli AU
J Clin Microbiol; 1995 Aug; 33(8):2086-90. PubMed ID: 7559953
[TBL] [Abstract][Full Text] [Related]
12. GPI-anchored glycoconjugates from Trypanosoma cruzi trypomastigotes are recognized by lytic anti-alpha-galactosyl antibodies isolated from patients with chronic Chagas' disease.
Almeida IC; Ferguson MA; Schenkman S; Travassos LR
Braz J Med Biol Res; 1994 Feb; 27(2):443-7. PubMed ID: 8081263
[TBL] [Abstract][Full Text] [Related]
13. The effect of reinoculation with trypomastigotes on the level of protective antibodies in mice chronically infected with T. cruzi.
Pereira ME; Krettli AU
Braz J Med Biol Res; 1990; 23(3-4):283-92. PubMed ID: 2128821
[TBL] [Abstract][Full Text] [Related]
14. Biological activity of chronic phase antibodies eluted from sensitized Trypanosoma cruzi trypomastigotes.
Umekita LF; Ramos DP; Barbaro KC; Mota I
Immunol Lett; 1999 Nov; 70(2):73-6. PubMed ID: 10569694
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent cell cytotoxicity against Trypanosoma cruzi is only mediated by protective antibodies.
Lima-Martins MV; Sanchez GA; Krettli AU; Brener Z
Parasite Immunol; 1985 Jul; 7(4):367-76. PubMed ID: 3929211
[TBL] [Abstract][Full Text] [Related]
16. [Soluble antigens released by Trypanosoma cruzi trypomastigotes used in ELISA to detect cure in chagasic patients following specific treatment].
Krautz GM; Coutinho MG; Galvão LM; Cançado JR; Krettli AU
Rev Soc Bras Med Trop; 1994; 27(4):199-207. PubMed ID: 7531867
[TBL] [Abstract][Full Text] [Related]
17. High resolution of Trypanosoma cruzi amastigote antigen in serodiagnosis of different clinical forms of Chagas' disease.
Matsumoto TK; Hoshino-Shimizu S; Nakamura PM; Andrade HF; Umezawa ES
J Clin Microbiol; 1993 Jun; 31(6):1486-92. PubMed ID: 8314991
[TBL] [Abstract][Full Text] [Related]
18. Detection of antibodies in sera from Chagas' disease patients using a Trypanosoma cruzi immunodominant recombinant antigen.
Paranhos-Bacalla GS; Santos MR; Cotrim PC; Rassi A; Jolivet M; Camargo ME; Da Silveira JF
Parasite Immunol; 1994 Mar; 16(3):165-9. PubMed ID: 8208589
[TBL] [Abstract][Full Text] [Related]
19. A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.
Zrein M; Granjon E; Gueyffier L; Caillaudeau J; Liehl P; Pottel H; Cardoso CS; Oliveira CDL; de Oliveira LC; Lee TH; Ferreira AM; Ribeiro ALP; Busch MP; Sabino EC
PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006226. PubMed ID: 29425201
[TBL] [Abstract][Full Text] [Related]
20. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives.
Krettli AU
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():142-51. PubMed ID: 19753469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
